Norris Comprehensive Cancer Center

Los Angeles, California 91011

2 studies enrolling now · 21 studies all time

What they study most

Advanced Solid Tumor, Breast Carcinoma, CRC, Carcinoma, Squamous Cell, Colorectal Cancer, Extra-Pancreatic Neuroendocrine Tumor (epNET), Germ Cell Neoplasm, HGSOC, Head and Neck Neoplasms, Head and Neck Squamous Cell Carcinoma, Hemoglobinuria, Paroxysmal, Hepatitis C

Studies at this site

• Zanzalintinib Versus Everolimus in Participants With Locally Advanced or Metastatic Neuroendocrine Tumors — Recruiting now
• A Study of TTI-101 as Monotherapy and in Combination in Participants With Locally Advanced or Metastatic, and Unresectable Hepatocellular Carcinoma — Recruiting now
• Study of Gemcitabine, Oxaliplatin, and Paclitaxel in Patients With Refractory Germ Cell Carcinoma — Completed
• Study of Lurbinectedin in Combination With Doxorubicin Versus Doxorubicin Alone as First-line Treatment in Participants With Metastatic Leiomyosarcoma (SaLuDo) — Running, not enrolling
• Study of Onvansertib in Combination With FOLFIRI and Bevacizumab or FOLFOX and Bevacizumab Versus FOLFIRI and Bevacizumab or FOLFOX and Bevacizumab for First-Line Treatment of Metastatic Colorectal Cancer in Adult Participants With a KRAS or NRAS Mutation — Running, not enrolling
• XTX202 in Patients With Advanced Solid Tumors — Completed
• A Study of Dazostinag as Single Agent and Dazostinag in Combination With Pembrolizumab in Adults With Advanced or Metastatic Solid Tumors — Completed
• MIT-001 for Prevention of CCRT-Induced OM in HNSCC Patients — Running, not enrolling
• A Study of KB-0742 in Participants With Relapsed or Refractory Solid Tumors Including Platinum Resistant High Grade Serous Ovarian Cancer (HGSOC) — Stopped early
• Study of Onvansertib in Combination With FOLFIRI and Bevacizumab Versus FOLFIRI and Bevacizumab for Second Line Treatment of Metastatic Colorectal Cancer in Participants With a Kirsten Rat Sarcoma Virus Gene (KRAS) or Neuroblastoma-RAS (NRAS) Mutation — Completed
• Study to Evaluate the Efficacy, Safety and Tolerability of Vibegron in Men With Overactive Bladder (OAB) Symptoms on Pharmacological Therapy for Benign Prostatic Hyperplasia (BPH) — Completed
• A Study of Momelotinib Versus Danazol in Symptomatic and Anemic Myelofibrosis Participants (MOMENTUM) — Completed
• Direct Acting Antiviral-Post Authorization Safety Study — Completed
• Bortezomib and Bevacizumab ("BB-mib-mab") in Patients With Advanced or Recurrent Renal Cell Cancer (RCC) — Status unconfirmed
• Clinical Trial of Gemcitabine and Oxaliplatin in Recurrent or Metastatic Breast Cancer — Stopped early
• Estramustine, Docetaxel, and Carboplatin for Patients With Hormone Refractory Prostate Cancer Progressing After Mitoxantrone-Based Chemotherapy. — Completed
• Clinical Trial of Docetaxel in Combination With Gemcitabine in Platinum-Resistant Ovarian Cancer and Primary Peritoneal Carcinoma — Completed
• Combination Therapy With Fludarabine, Mitoxantrone and Rituximab in Mantle Cell Lymphoma — Stopped early
• A Pilot Clinical Trial to Evaluate the Biological Activity of Fulvestrant in Breast Ductal Carcinoma in Situ (DCIS) — Stopped early
• A Study of ARQ 501 in Patients With Squamous Cell Carcinoma of the Head and Neck — Completed
• Study of Safety in Hemolytic Paroxysmal Nocturnal Hemoglobinuria (PNH) Patients Treated With Eculizumab — Completed